| 產(chǎn)品編號 | bs-0522R |
| 英文名稱 | Rabbit Anti-CD45 antibody |
| 中文名稱 | 白細(xì)胞共同抗原CD45抗體 |
| 別 名 | B220; CD 45; CD-45; cd45 antigen; ec3.1.3.48; CD45R; GP180; GP180; GP 180; L CA; LCA; L-CA; Leukocyte common antigen; LY5; Ly-5 glycoprotein; Protein tyrosine phosphatase receptor type C; Protein tyrosine phosphatase receptor type c polypeptide; protein tyrosine phosphatase, receptor type, C; Receptor-type tyrosine-protein phosphatase C; PTPRC; PTPRC_HUMAN; SCID due to PTPRC deficiency; T200; T200 glycoprotein; T200 leukocyte common antigen; Human homolog of severe combined immunodeficiency due to PTPRC deficiency. |
 |
Specific References (20) | bs-0522R has been referenced in 20 publications.
|
| 研究領(lǐng)域 | 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 干細(xì)胞 轉(zhuǎn)錄調(diào)節(jié)因子 細(xì)胞表面分子 糖蛋白 細(xì)胞類型標(biāo)志物 自然殺傷細(xì)胞 淋巴細(xì)胞 t-淋巴細(xì)胞 b-淋巴細(xì)胞 細(xì)胞膜蛋白 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse,Rat,Rabbit (predicted: Cow) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,Flow-Cyt=1μg/Test,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 143kDa |
| 檢測分子量 | 220 |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CD45: 1210-1304/1304 <Cytoplasmic> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus belongs to receptor type PTP. This gene is specifically expressed in hematopoietic cells. This PTP has been shown to be an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. This PTP also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling. Four alternatively spliced transcripts variants of this gene, which encode distinct isoforms, have been reported. [provided by RefSeq, Jul 2008]. Function: Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity. Subunit: Binds GANAB and PRKCSH. Interacts with SKAP1. Interacts with DPP4; the interaction is enhanced in a interleukin-12-dependent manner in activated lymphocytes. Contains 2 tyrosine-protein phosphatase domains. Subcellular Location: Membrane; Single-pass type I membrane protein. Membrane raft. Note=Colocalized with DPP4 in membrane rafts. Post-translational modifications: Heavily N- and O-glycosylated. DISEASE: Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain. Similarity: Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily. Contains 2 fibronectin type-III domains. Contains 2 tyrosine-protein phosphatase domains. SWISS: P08575 Gene ID: 5788 Database links: Entrez Gene: 5788 Human Entrez Gene: 19264 Mouse Omim: 151460 Human SwissProt: P08575 Human SwissProt: P06800 Mouse Unigene: 654514 Human Unigene: 391573 Mouse Unigene: 90166 Rat CD45在活化信號轉(zhuǎn)導(dǎo)中起到調(diào)節(jié)作用 在確定CD45為一種PTPase之前就已證實了CD45參于細(xì)胞的活化和生長調(diào)節(jié)。 抗CD45抗體可以抑制PHA或CD3交聯(lián)所介導(dǎo)的T細(xì)胞增殖，還可抑制NK或細(xì)胞毒性T細(xì)胞對靶細(xì)胞的殺傷，抑制經(jīng)CD2、CD3以及CD8膜分子介導(dǎo)的信號轉(zhuǎn)導(dǎo)作用。 白細(xì)胞共同抗原是五種或更多的高分子量糖蛋白組成的蛋白家族，主要位于白細(xì)胞表面，包括T、B淋巴細(xì)胞、多形核白細(xì)胞、單核細(xì)胞等，而在紅細(xì)胞、血小板及非造血系統(tǒng)中不表達(dá)。因此是區(qū)分淋巴瘤/白血病和非造血組織腫瘤（如未分化小細(xì)胞癌、小圓細(xì)胞肉瘤）的特異性標(biāo)記物。該抗體主要用于淋巴瘤和未分化小細(xì)胞癌的鑒別診斷。 |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Rat Spleen tissue lysates
Lane 2: Rat Thymus tissue lysates
Primary: Anti-CD45 (bs-0522R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 220 kDa
Observed band size: 210 kDa
Blank control (blue line): Rabbit spleen cells(blue).
Primary Antibody (green line): Rabbit Anti-CD45/FITC Conjugated antibody (bs-0522R-FITC)
Dilution: 1μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG-FITC.
Protocol
The cells were fixed with 70% ice-cold methanol overnight at 4℃ . The cells were then incubated in 1 X PBS/2%BSA/10% goat serum to block non-specific protein-protein interactions followed by the antibody for 15 min at room temperature. Cells stained with Primary Antibody for 30 min at room temperature.Acquisition of 20,000 events was performed.
Blank control: Raji(blue). Primary Antibody:Rabbit Anti- CD45 antibody(bs-0522R), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG(orange) ,used under the same conditions ); Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA.
Protocol
The cells were washed twice with phosphate-buffered saline (PBS).The cells were then incubated in 1 X PBS containing 0.5% BSA + 10% goat serum (15 min) to block non-specific protein-protein interactions followed by the antibody (bs-0522R, 1μg /1x10^6 cells) for 30 min on ice. The secondary antibody used was Goat Anti-rabbit IgG/PE antibody at 1/200 dilution for 30 min on ice. Acquisition of 20,000 events was performed.
Blank control: Jurkat.
Primary Antibody (green line): Rabbit Anti-CD45 antibody (bs-0522R)
Dilution: 2μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody : Goat anti-rabbit IgG-PE
Dilution: 1μg /test.
Protocol
The cells were incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
Blank control: Molt4.
Primary Antibody (green line): Rabbit Anti-CD45 antibody (bs-0522R)
Dilution: 2μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody : Goat anti-rabbit IgG-PE
Dilution: 1μg /test.
Protocol
The cells were incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
